Our Publications
As a science-driven company, we proudly publish numerous scientific papers every year in high-impact journals. Please feel free to contact our Science-team if you have questions or comments to our publications, or proposals for new scientific collaborations: science@nbcd.com3 publications found
May 07, 2021
The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safety results.
Journals:
Annals of the Rheumatic Diseases
Authors:
Eckstein F
, Hochberg MC
, Guehring H
, Moreau F
, Ona V
, Bihlet AR
, Byrjalsen I
, Andersen JR
, Daelken B
, Guenther O
, Ladel C
, Michaelis M
, Conaghan PG
Osteoarthritis
March 11, 2021
To assess pain outcomes and cartilage thickness change in a subgroup at risk (SAR) of further progression in the FORWARD trial of knee osteoarthritis patients treated with sprifermin.
Journals:
Seminars in Arthritis and Rheumatism
Authors:
Guehring H
, Moreau F
, Daelken B
, Ladel C
, Guenther O
, Bihlet AR
, Wirth W
, Eckstein F
, Hochberg MC
, Conaghan PG
Osteoarthritis
October 08, 2019
FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) was a 5-year, dose-finding, multicenter randomized clinical trial conducted at 10 sites. Eligible participants were aged 40 to 85 years with symptomatic, radiographic knee osteoarthritis and Kellgren-Lawrence grade 2 or 3. Enrollment began in July 2013 and ended in May 2014; the last participant visit occurred on May 8, 2017. The primary outcome at 2 years and a follow-up analysis at 3 years are reported.
Journals:
JAMA
Authors:
Hochberg MC
, Guermazi A
, Guehring H
, Aydemir A
, Wax S
, Fleuranceau-Morel P
, Bihlet AR
, Byrjalsen I
, Andersen JR
, Eckstein F
Osteoarthritis